EXHIBIT C

DEPARTMENT OF HEALTH, STATE BOARD OF HEALTH

SUBJECT: List of Controlled Substances

DESCRIPTION: The proposed listed amendments update the List of Controlled Substances to include these drugs:

1. Meta-fluorofentanyl [other name(s): N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (RR).

2. Meta-fluoroisobutyryl fentanyl [other name(s): N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide]. The DEA has placed this opioid analgesic into Schedule I because it has norecognized medical use. This drug would be included as Schedule I to follow DEA. Page 5,Schedule I, (b), (51), (vi), (SS).

3. Para-methoxyfuranyl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide]. The DEA has placed this opioid analgesic into Schedule I becauseit has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (TT).

4. Para-methylcyclopropyl fentanyl [other name(s): N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide]. The DEA has placed this opioid analgesicinto Schedule I because it has no recognized medical use. This drug would be included asSchedule I to follow DEA. Page 5, Schedule I, (b), (51), (vi), (UU).

5. 3-furanyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide]. The DEA has placed this opioid analgesic into Schedule I because it has norecognized medical use. This drug would be included as Schedule I to follow DEA. Page 5,Schedule I, (b), (51), (vi), (VV).

6. 2′,5′-dimethoxyfentanyl [other name(s): N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page5, Schedule I, (b), (51), (vi), (WW).

7. Isovaleryl fentanyl [other name(s): 3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 5,Schedule I, (b), (51), (vi), (XX).

8. Ortho-fluorofuranyl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide. The DEA has placed this opioid

analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 6, Schedule I, (b), (51), (vi), (YY).

9. Alpha′-methyl butyryl fentanyl [other name(s): 2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide]. The DEA has placed this opioid analgesic into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 6, Schedule I, (b), (51), (vi), (ZZ).

10. Etodesnitazene [other name(s): Etazene], N-Pyrrolidino Etonitazene (other name(s) Etonitazepyne), and Protonitazene are Schedule I controlled substances. To follow DEA, controlled substance code numbers have been set forth opposite of these substances. Page 6, Schedule I, (b), (54), (vi), (E), Page 6, Schedule I, (b), (54), (vi), (O), and Page 6, Schedule I, (b), (54), (vi), (Q).

11. 2-Methyl AP–237. [other name(s): 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one]. The DEA has placed this synthetic opioid into Schedule I because it has no recognized medical use. This drug would be included as Schedule I to follow DEA. Page 7, Schedule I, (b), (55).

12. 3-methylmethcathinone (other names: 3–MMC). The DEA has identified this synthetic cathinone as a positional isomer of mephedrone a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule I with subsequent numbering changes to follow. Page 13, Schedule I, (f), (2), (xvii).

13. 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one [other names: alpha-PiHP, and Alpha-Pyrrolidinoisohexanophenone). The DEA has identified this synthetic cathinone as a positional isomer of Alpha-PHP a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule I. Page 14, Schedule I, (f), (2), (xxviii).

14. The following items are marked for clean up:
    a. Page 2, Schedule I, (b), (46);
    b. Page 3, Schedule I, (b), (51), (vi), (B);
    c. Page 3, Schedule I, (b), (51), (vi), (C);
    d. Page 3, Schedule I, (b), (51), (vi), (G);
    e. Page 3, Schedule I, (b), (51), (vi), (I);
    f. Page 4, Schedule I, (b), (51), (vi), (N);
    g. Page 12, Schedule I, (f), (1), (iv);
    h. Page 12, Schedule I, (f), (1), (ix);
    i. Page 12, Schedule I, (f), (1), (xi);
    j. Page 13, Schedule I, (f), (2), (iii);
    k. Page 17. Schedule II, (d), (3);
    l. Page 19, Schedule III, (c), (13);

m. Page 23, Schedule III, (g), (51); and
n. Page 27, Schedule IV, (d), (1).

15. Xylazine The potential adverse health effects when abused, and increasing national prevalence of xylazine utilized as an adulterating agent to other illicit substances poses a threat to public health and safety. The substance will be included as a Schedule III controlled substance, Page 19, Schedule III, (c), (15), (i through vi), with outlined exceptions utilizing the following language:

    Xylazine and any material, compound, mixture, or preparation which contains any quantity of xylazine, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, except in the following uses:

    i. Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States Secretary of Health and Human Services under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b);
    ii. Dispensing, prescribing, or administering xylazine to an animal that is permissible under section 512 (a)(4) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(a)(4));
    iii. Possessing a drug containing xylazine, as described in this Section (15), for animal use:
        (A) By a licensed pharmacist or licensed veterinarian; or
        (B) Pursuant to a valid prescription from a licensed veterinarian.
    iv. Possessing, manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug either:
        (A) Approved under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b); or
        (B) Issued an investigation use exemption under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(j));
    v. Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or
    vi. Another use approved or permissible under the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301, et seq.) or under 21 CFR Part 530, Subpart B.

16. Zuranolone. The FDA approved this drug for use in treatment of post-partum depression. This drug would be included as Schedule IV to follow DEA. Page 27, Schedule IV, (c), (61).

17. ADB–BUTINACA or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide. The DEA has identified this synthetic cannabinoid as positional isomer of AB-PINACA, a currently listed controlled substance. This drug without a recognized medical use would be included as Schedule VI. Page 36, Schedule VI, (a), (5), (xi), (LL).

PUBLIC COMMENT: A public hearing was held on this rule on January 7, 2025. The public comment period expired on January 1, 2025. The agency provided the following public comment summary:

Commenter's Name: Bill Paschall, Arkansas Cannabis Industry Association
COMMENT: RULE: SCHEDULE VI(A)(2) – "Tetrahydrocannabinols, unless the tetrahydrocannabinol is:"

Schedule VI(a)(2) should be amended as follows:

> "Tetrahydrocannabinols, and their acidic precursors, unless the tetrahydrocannabinol is:…"

The addition of this language will make enforcement of the Arkansas Controlled Substances Act (ACSA) consistent with federal guidance issued by the Drug Enforcement Administration (DEA), per the attached letter. A failure to specify that acidic precursors are included in prohibited tetrahydracannabinols has led to the proliferation of intoxicating hemp-derived products (frequently marketed to minors) sold over the counter throughout the United States. *See* Matthew E. Rossheim, PhD, et al. (2024, November) Intoxicating Cannabis Products in Vape Shops: United States, 2023. American Journal of Preventative Medicine, 67(5), 776-784. https://www.ajpmonline.org/article/S0749-3797(24)00229-0/abstract
RESPONSE: The Department of Health will consider the suggested language for future rule promulgation, however, with the current litigation regarding Acts of 2023 and recent Acts of 2025 that may affect this section of the List, the Department has determined the suggested change must be further reviewed.

The proposed effective date is pending legislative review and approval.

FINANCIAL IMPACT: The agency indicated that this rule has no financial impact.

LEGAL AUTHORIZATION: The Department of Health administers the Uniform Controlled Substances Act and has authority to add substances to the Controlled Substances List and to delete or reschedule "any substance enumerated in a schedule[.]" Ark. Code Ann. § 5-64-201(a)(1)(A)(i). "The Secretary of the Department of Health shall revise and republish the schedules annually." Ark. Code Ann. § 5-64-216. If a substance is controlled under federal law, the Department "shall similarly control the substance" unless the Secretary objects to inclusion within thirty days of publication in the Federal Register of a final order designating a substance as a controlled substance. Ark. Code Ann. § 5-64-201(d).

QUESTIONNAIRE FOR FILING PROPOSED RULES WITH THE ARKANSAS LEGISLATIVE COUNCIL

DEPARTMENT Arkansas Department of Health
BOARD/COMMISSION Division for Health Protection, Pharmacy Services Section
BOARD/COMMISSION DIRECTOR Shane David, PharmD, Branch Chief
CONTACT PERSON Laura Shue, General Counsel
ADDRESS 4815 West Markham Street, Slot 31, Little Rock, AR 72205
PHONE NO. (501) 661-2297 **EMAIL** Laura.Shue@arkansas.gov
NAME OF PRESENTER(S) AT SUBCOMMITTEE MEETING
Laura Shue; Shane David
PRESENTER EMAIL(S) Laura.Shue@arkansas.gov; Shane.David@arkansas.gov

INSTRUCTIONS

In order to file a proposed rule for legislative review and approval, please submit this Legislative Questionnaire and Financial Impact Statement, and attach (1) a summary of the rule, describing what the rule does, the rule changes being proposed, and the reason for those changes; (2) both a markup and clean copy of the rule; and (3) all documents required by the Questionnaire.

If the rule is being filed for permanent promulgation, please email these items to the attention of Rebecca Miller-Rice, miller-ricer@blr.arkansas.gov, for submission to the Administrative Rules Subcommittee.

If the rule is being filed for emergency promulgation, please email these items to the attention of Director Marty Garrity, garritym@blr.arkansas.gov, for submission to the Executive Subcommittee.

Please answer each question completely using layman terms.

****

1. What is the official title of this rule?
List of Controlled Substances

2. What is the subject of the proposed rule? Updates to items based on DEA scheduling of substances and requ

3. Is this rule being filed under the emergency provisions of the Arkansas Administrative Procedure Act? Yes ☐ No ☑

If yes, please attach the statement required by Ark. Code Ann. § 25-15-204(c)(1).

If yes, will this emergency rule be promulgated under the permanent provisions of the Arkansas Administrative Procedure Act? Yes ☐ No ☐

4. Is this rule being filed for permanent promulgation? Yes ☑ No ☐

If yes, was this rule previously reviewed and approved under the emergency provisions of the Arkansas Administrative Procedure Act? Yes ☐ No ☑

If yes, what was the effective date of the emergency rule? _____

On what date does the emergency rule expire?_____

5. Is this rule required to comply with a *federal* statute, rule, or regulation? Yes ☐ No ☑

If yes, please provide the federal statute, rule, and/or regulation citation.

6. Is this rule required to comply with a *state* statute or rule? Yes ☑ No ☐

If yes, please provide the state statute and/or rule citation.

Ark. Code Ann. § 5-64-216; Ark. Code Ann. § 5-64-101, et seq. (Supp. 2023)

7. Are two (2) rules being repealed in accord with Executive Order 23-02? Yes ☐ No ☑

If yes, please list the rules being repealed.
If no, please explain.

The Arkansas Department of Health is mandated to update the Controlled Substances List each year based on changes by the DEA for scheduling of substances, and requests by interested state agencies.

8. Is this a new rule? Yes ☐ No ☑

Does this repeal an existing rule? Yes ☐ No ☑
If yes, the proposed repeal should be designated by strikethrough. If it is being replaced with a new rule, please attach both the proposed rule to be repealed and the replacement rule.

Is this an amendment to an existing rule? Yes ☑ No ☐
If yes, all changes should be indicated by strikethrough and underline. In addition, please be sure to label the markup copy clearly as the markup.

9. What is the state law that grants the agency its rulemaking authority for the proposed rule, outside of the Arkansas Administrative Procedure Act? Please provide the specific Arkansas Code citation(s), including subsection(s).

Ark. Code § 5-64-201, § 5-64-702

10. Is the proposed rule the result of any recent legislation by the Arkansas General Assembly?
Yes ☐ No ☑

If yes, please provide the year of the act(s) and act number(s).

11. What is the reason for this proposed rule? Why is it necessary?

See Attached Summary of Changes.

12. Please provide the web address by which the proposed rule can be accessed by the public as provided in Ark. Code Ann. § 25-19-108(b)(1).

https://www.healthy.arkansas.gov/proposed-amendment-to-existing-rules

13. Will a public hearing be held on this proposed rule? Yes ☑ No ☐

If yes, please complete the following:

Date: 01/07/2025

Time: 1:30 pm

Place: Arkansas Department of Health, Room 2508, located at 4815 West Markham, Little Rock, Arkansas, 7220

Please be sure to advise Bureau Staff if this information changes for any reason.

14. On what date does the public comment period expire for the permanent promulgation of the rule? Please provide the specific date. 01/07/2025

15. What is the proposed effective date for this rule? 05/01/2025

16. Please attach (1) a copy of the notice required under Ark. Code Ann. § 25-15-204(a)(1) and (2) proof of the publication of that notice.

17. Please attach proof of filing the rule with the Secretary of State, as required by Ark. Code Ann. § 25-15-204(e)(1)(A).

18. Please give the names of persons, groups, or organizations that you anticipate will comment on these rules. Please also provide their position (for or against), if known.

Arkansas Veterinary Medical Association, Arkansas Cattleman's Association

19. Is the rule expected to be controversial? Yes ☐ No ☑

If yes, please explain.

FINANCIAL IMPACT STATEMENT

PLEASE ANSWER ALL QUESTIONS COMPLETELY.

DEPARTMENT Arkansas Department of Health
BOARD/COMMISSION Division for Health Protection, Pharmacy Services Section
PERSON COMPLETING THIS STATEMENT Laura Shue, General Counsel
TELEPHONE NO. (501) 661-2297 **EMAIL** Laura.Shue@arkansas.gov

To comply with Ark. Code Ann. § 25-15-204(e), please complete the Financial Impact Statement and email it with the questionnaire, summary, markup and clean copy of the rule, and other documents. Please attach additional pages, if necessary.

TITLE OF THIS RULE List of Controlled Substances

1. Does this proposed, amended, or repealed rule have a financial impact?
   Yes ☐ No ☑

2. Is the rule based on the best reasonably obtainable scientific, technical, economic, or other evidence and information available concerning the need for, consequences of, and alternatives to the rule?
   Yes ☑ No ☐

3. In consideration of the alternatives to this rule, was this rule determined by the agency to be the least costly rule considered? Yes ☑ No ☐

   If no, please explain:

   (a) how the additional benefits of the more costly rule justify its additional cost;

   (b) the reason for adoption of the more costly rule;

   (c) whether the reason for adoption of the more costly rule is based on the interests of public health, safety, or welfare, and if so, how; and

   (d) whether the reason for adoption of the more costly rule is within the scope of the agency's statutory authority, and if so, how.

4. If the purpose of this rule is to implement a *federal* rule or regulation, please state the following:

   (a) What is the cost to implement the federal rule or regulation? n/a

Current Fiscal Year		**Next Fiscal Year**	
General Revenue		General Revenue	
Federal Funds		Federal Funds	
Cash Funds		Cash Funds	
Special Revenue		Special Revenue	
Other (Identify)		Other (Identify)	
Total	$0.00	Total	$0.00

(b) What is the additional cost of the state rule?

Current Fiscal Year		**Next Fiscal Year**	
General Revenue		General Revenue	
Federal Funds		Federal Funds	
Cash Funds		Cash Funds	
Special Revenue		Special Revenue	
Other (Identify)		Other (Identify)	
Total	$0.00	Total	$0.00

5. What is the total estimated cost by fiscal year to any private individual, private entity, or private business subject to the proposed, amended, or repealed rule? Please identify those subject to the rule, and explain how they are affected.

Current Fiscal Year	**Next Fiscal Year**
$ 0.00	$ 0.00

6. What is the total estimated cost by fiscal year to a state, county, or municipal government to implement this rule? Is this the cost of the program or grant? Please explain how the government is affected.

Current Fiscal Year	**Next Fiscal Year**
$ 0.00	$ 0.00

7. With respect to the agency's answers to Questions #5 and #6 above, is there a new or increased cost or obligation of at least one hundred thousand dollars ($100,000) per year to a private individual, private entity, private business, state government, county government, municipal government, or to two (2) or more of those entities combined?

Yes ☐ No ☑

If yes, the agency is required by Ark. Code Ann. § 25-15-204(e)(4) to file written findings at the time of filing the financial impact statement. The written findings shall be filed simultaneously with the financial impact statement and shall include, without limitation, the following:

(1) a statement of the rule's basis and purpose;

(2) the problem the agency seeks to address with the proposed rule, including a statement of whether a rule is required by statute;

(3) a description of the factual evidence that:
(a) justifies the agency's need for the proposed rule; and
(b) describes how the benefits of the rule meet the relevant statutory objectives and justify the rule's costs;

(4) a list of less costly alternatives to the proposed rule and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;

(5) a list of alternatives to the proposed rule that were suggested as a result of public comment and the reasons why the alternatives do not adequately address the problem to be solved by the proposed rule;

(6) a statement of whether existing rules have created or contributed to the problem the agency seeks to address with the proposed rule and, if existing rules have created or contributed to the problem, an explanation of why amendment or repeal of the rule creating or contributing to the problem is not a sufficient response; and

(7) an agency plan for review of the rule no less than every ten (10) years to determine whether, based upon the evidence, there remains a need for the rule including, without limitation, whether:
(a) the rule is achieving the statutory objectives;
(b) the benefits of the rule continue to justify its costs; and
(c) the rule can be amended or repealed to reduce costs while continuing to achieve the statutory objectives.

List Of Controlled Substances

For the State Of Arkansas

Pursuant to the provisions of Arkansas Code Annotated § 5-64-201 and § 5-64-216 of the laws of the State of Arkansas, the Secretary of the Arkansas Department of Health or duly authorized agent, as specified by law, is giving public notice of the publication of the List of Controlled Substances for the State of Arkansas.

Due consideration has been given applicable federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

Based on these considerations the attached listing of the Schedule of Controlled Substances and the corresponding drugs that are included in each schedule is hereby promulgated by the Secretary of the Arkansas Department of Health as the List of Controlled Substances for the State of Arkansas.

Each controlled substance or basic class thereof has been assigned an "Administration Controlled Substance Code Number" for purposes of identification. These numbers are for internal management and are used as a means to identify substances with complex and cumbersome chemical names.

Next to the code number is the date the substance was placed in schedule by the Secretary of the Arkansas Department of Health. A "*" denotes the substance was scheduled prior to April, 1979.

I, Shane David, Pharm.D., Branch Chief, Health Systems Licensing and Certifications ~~Section Chief of Pharmacy Services~~ for the Arkansas Department of Health, do hereby certify that the documents attached hereto are true and correct copies of the current List of Controlled Substances adopted by the Arkansas State Board of Health in accordance with Arkansas state law.

Shane David, Pharm.D., ~~**Branch Chief**~~
~~Pharmacy Services Section~~

STATE OF ARKANSAS)
)
COUNTY OF SALINE)

I, Marci Middleton-Yates, do hereby certify that Shane David, Pharm.D., well known to me, appeared before me and signed the above referenced document.

Sworn and subscribed to before me this _____ day of ~~March~~, 2024.

Notary Public

My commission expires

ARKANSAS DEPARTMENT OF HEALTH

LIST OF CONTROLLED SUBSTANCES

SECTION I AUTHORITY

The following scheduling of these controlled substances has been hereby promulgated pursuant to Arkansas Code Annotated §5-64-201 and §5-64-216.

SECTION II PURPOSE

Due consideration has been given applicable Federal regulations, current scientific knowledge regarding the listed substances, the evidence of actual or relative potential for abuse, the history and current patterns of abuse, the risk to the public health, and potential to produce psychic or psychological dependence liability.

SECTION III GENERAL REQUIREMENTS

(Attached copy of the listing of scheduling of controlled substances)

SECTION IV REPEAL

All lists of schedules of controlled substances in conflict herewith are hereby repealed.

CERTIFICATION

This will certify the following list of scheduling of controlled substances was adopted by the Arkansas State Board of Health at a session of the Board held in Little Rock, Arkansas on the ~~26th~~ ____day of October, ~~2023~~2024, and after a Public Hearing on the ~~23rd day of January, 2024~~, held in Little Rock, Arkansas, at the State Department of Health Building.

_____

Jennifer Dillaha, MD
Secretary of Arkansas State Board of Health
Director of the Arkansas Department of Health

ARTICLE II

SCHEDULE I

(a) Schedule I shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of such isomers, esters, ethers, salts is possible within the specific chemical designation (for purposes of 3-methylthiofentanyl only, the term isomer includes the optical and geometric isomers):

(1) Acetylmethadol ---------- 9601*
(2) Allylprodine ---------- 9602*
(3) Alphacetylmethadol (except Levo-alphacetylmethadol (LAAM) ---------- 9603*
(4) Alphameprodine ---------- 9604*
(5) Alphamethadol ---------- 9605*
(6) Benzethidine ---------- 9606*
(7) Betacetylmethadol ---------- 9607*
(8) Betameprodine ---------- 9608*
(9) Betamethadol ---------- 9609*
(10) Betaprodine ---------- 9611*
(11) Dextromoramide ---------- 9613*
(12) Diampromide ---------- 9615*
(13) Diethylthiambutene ---------- 9616*
(14) Difenoxin ---------- 9168*
(15) Dimenoxadol ---------- 9617*
(16) Dimepheptanol ---------- 9618*
(17) Dimethylthiambutene ---------- 9619*
(18) Dioxaphetyl butyrate ---------- 9621*
(19) Dipipanone ---------- 9622*
(20) Ethylmethylthiambutene ---------- 9623*
(21) Etoxeridine ---------- 9625*
(22) Furethidine ---------- 9626*
(23) Hydroxypethidine ---------- 9627*

(24) Ketobemidone ---------- 9628*

(25) Levomoramide ---------- 9629*

(26) Levophenacylmorphan ---------- 9631*

(27) Morpheridine ---------- 9632*

(28) MPPP [other name(s): (1-methyl-4-phenyl-4-propionoxypiperidine)] ---------- 9661-(10-1985)

(29) Noracymethadol ---------- 9633*

(30) Norlevorphanol ---------- 9634*

(31) Normethadone ---------- 9635*

(32) Norpipanone ---------- 9636*

(33) PEPAP [other name(s): 1-(2-phenylethyl)-4-phenyl-4 acetyloxypiper-idine] - 9663-(10-1985)

(34) Phenadoxone ---------- 9637*

(35) Phenampromide ---------- 9638*

(36) Phenomorphan ---------- 9647*

(37) Phenoperidine ---------- 9641*

(38) Piritramide ---------- 9642*

(39) Proheptazine ---------- 9643*

(40) Properidine ---------- 9644*

(41) Propiram ---------- 9649*

(42) Racemoramide ---------- 9645*

(43) Tilidine ---------- 9750-(9-1981)

(44) Trimeperidine ---------- 9646*

(45) Acetyl norfentanyl [other name(s): N-phenyl-N-4-piperidinyl-acetamide]----------(4-2017)

(46) AH-7921 [other name(s): 3,4-dichloro-N-[(1~~N-[(1~~-dimethylamino)cyclohexylmethyl]benzamide]----------9551-(4-2017)

(47) W-18 [other name(s): 1-(4-nitrophenylethyl)piperidylidene-2-(4-chlorophenyl)sulfonamide]----------(4-2017)

(48) W-15 [other name(s): 1-phenylethylpiperidylidene-2-(4-chlorophenyl)Sulfonamide] ----------(4-2017)

(49) MT-45 [other name(s): 1-cyclohexyl-4-(1,2-diphenylethyl)piperazine] ---------- 9560-(4-2017)

(50) U-47700 [other name(s): trans-3,4-dichloro-N-(2-(dimethylamino)cyclohexyl)-N-methylbenzamide] ---------- 9547-(4-2017)

(51) Fentanyl-related substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Fentanyl-related substance means any substance not otherwise listed, and for which no exemption or approval is in effect under section

505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that is structurally related to fentanyl by one or more of the following modifications: ----------(4-2021)

(i) Replacement of the phenyl portion of the phenethyl group by any monocycle, whether or not further substituted in or on the monocycle;

(ii) Substitution in or on the phenethyl group with alkyl, alkenyl, alkoxyl, hydroxyl, halo, haloalkyl, amino or nitro groups;

(iii) Substitution in or on the piperidine ring with alkyl, alkenyl, alkoxyl, ester, ether, hydroxyl, halo, haloalkyl, amino or nitro groups;

(iv) Replacement of the aniline ring with any aromatic monocycle whether or not further substituted in or on the aromatic monocycle; or

(v) Replacement of the N-propionyl group by another acyl group.

(vi) Fentanyl-related substances shall include, but are not limited to:

(A) Acetyl-alpha-methylfentanyl [other name(s): (N-[1-[1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide)] ----------9815-(2-1986)

(B) Alpha-methylfentanyl [other name(s): (N-[1-(alpha-methyl-beta-phenyl) ethyl-4-piperidyl] propronanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine)] ---------- 9814-(6-1982)

(C) Alpha-methylthiofentanyl [other name(s): N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide] ---------- 9832-(2-1986)

(D) Beta-hydroxyfentanyl [other name(s): (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide)] ---------- 9830-(2-1986)

(E) Beta-hydroxy-3-methylfentanyl [other name(s): N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropamamide] ---------- 9831-(2-1986)

(F) 3-Methylfentanyl [other name(s): (N-[3-Methyl-1-(2-phenylethyl)-4-piperidyl]-N-Phenylpropanamide)] ---------- 9813-(10-1985)

(G) 3-methylthiofentanyl [other name(s): N-[(3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide] ---------- 9833-(2-1986)

(H) Para-fluorofentanyl [other name(s): (N-[4-fluorophenyl)-N-[1-(2-phenenthyl)-4-piperindinyl]propananmide] ---------- 9812-(11-1986)

(I) Thiofentanyl [other name(s): (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide] ----------9835-(2-1986)

(J) Acetyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] ----------9821-(4-2017)

(K) Butyryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide]----------9822-(4-2017)

(L) Beta-hydroxythiofentanyl [other name(s): N-{1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl}-N-phenylpropionamide]----------9836-(4-2017)

(M) Acetyl fentanyl 4-methylphenethyl analog [other name(s): N-{1-[2-(4-methylphenyl)ethyl]-4-piperidinyl}-N-phenyl-acetamide] ---------- (4-2017)

(N) Valeryl fentanyl [other name(s): N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide] ---------- 9840-(4-2017)

(O) Furanyl fentanyl [other name(s): N-(1-(2-phenylethyl)-4-piperidinyl)-N-phenylfuran-2-carboxamide] ---------- 9834-(4-2017)

(P) Isobutyryl fentanyl [other name(s): 2-methyl-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide] ---------- 9827-(4-2017)

(Q) Ocfentanil [other name(s): N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide] ---------- 9838-(4-2017)

(R) 4-methoxy butyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ---------- (4-2017)

(S) Para-fluorobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide] ---------- 9823-(4-2017)

(T) Acryl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] ---------- 9811-(6-2020)

(U) 4-Fluoroisobutyryl fentanyl [other name(s): N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ---------- 9824-(6-2020)

(V) Tetrahydrofuranyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide] ---------- 9843-(6-2020)

(W) Cyclopropyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide] ---------- 9845-(4-2021)

(X) Methoxyacetyl fentanyl [other name(s): 2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide] ---------- 9825-(4-2021)

(Y) Ortho-fluorofentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide] ---------- 9816-(4-2021)

(Z) Crotonyl fentanyl [other name(s): (E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide] ---------- 9844-(5-2022)

(AA) Cyclopentyl fentanyl [other name(s): N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide] ---------- 9847-(5-2022)

(BB) Para-chloroisobutyryl fentanyl [other name(s): N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] ---------- 9826-(5-2022)

(CC) Para-methoxybutyryl fentanyl [other name(s): N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide] ---------- 9837-(5-2022)

(DD) Beta-methyl fentanyl [other name(s): N-phenyl-N-(1-(2-phenylpropyl) piperidin-4-yl)propionamide] ---------- 9856-(5-2022)

(EE) Beta'-phenyl fentanyl [other name: N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide] ---------- 9842-(5-2022)

(YY) Ortho-fluorofuranyl fentanyl [other name(s): N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide] ---------- 9863

(ZZ) Alpha′-methyl butyryl fentanyl [other name(s): 2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide] ---------- 9864

(52) Zipeprol ---------- 9873

(53) Brorphine ---------- 9098

(54) Benzimidazole-opioid substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzimidazole-opioid substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has benzimidazole ring with an ethylamine at its 1-position and benzyl group at its 2-position:

(i) With or without substitution on the benzimidazole;

(ii) With or without substitution at the ethylamine;

(iii) With or without inclusion of the ethylamine in a cyclic structure;

(iv) With or without substitution on the benzyl ring; or

(v) With or without replacement of the benzyl ring with an aromatic ring.

(vi) Benzimidazole-opioid substances shall include but are not limited to:

(A) 4'-Hydroxy Nitazene;

(B) 5-Aminoisotonitazene;

(C) Butonitazene;

(D) Clonitazene; ---------- 9612 *

(E) Etodesnitazene, [other name(s): Etazene]; ---------- 9765

(F) Etonitazene ; ---------- 9624*

(G) Flunitazene;

(H) Isotonitazene; ---------- 9614

(I) Isotodesnitazene;

(J) Metodesnitazene;

(K) Metonitazene; ---------- 9757

(L) N-Desethyl Etonitazene;

(M) N-Desethyl Isotonitazene ;

(N) N-Piperidinyl Etonitazene [other name(s): Etonitazepipne];

(O) N-Pyrrolidino Etonitazene [other name(s): Etonitazepyne]; ---------- 9758

(P) N-Pyrrolidino Protonitazene; and

(Q) Protonitazene ---------- 9759

(55) 2-Methyl AP–237 [other name(s): 1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one] ---------- 9664

(c) **Opium derivatives: (Narcotic Drugs)** Unless specifically excepted or unless listed in another schedule, any of the following opium derivatives, its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Acetorphine ---------- 9319*

(2) Acetyldihydrocodeine ---------- 9051*

(3) Benzylmorphine ---------- 9052*

(4) Codeine methylbromide ---------- 9070*

(5) Codeine-N-Oxide ---------- 9053*

(6) Cyprenorphine ---------- 9054*

(7) Desomorphine ---------- 9055*

(8) Dihydromorphine ---------- 9145*

(9) Drotebanol ---------- 9335*

(10) Etorphine (except hydrochloride salt) ---------- 9056*

(11) Heroin ---------- 9200*

(12) Hydromorphinol ---------- 9301*

(13) Methyldesorphine ---------- 9302*

(14) Methyldihydromorphine ---------- 9304*

(15) Morphine methylbromide ---------- 9305*

(16) Morphine methylsulfonate ---------- 9306*

(17) Morphine-N-Oxide ---------- 9307*

(18) Myrophine ---------- 9308*

(19) Nicocodeine ---------- 9309*

(20) Nicomorphine ---------- 9312*

(21) Normorphine ---------- 9313*

(22) Pholcodine ---------- 9314*

(23) Thebacon ---------- 9315*

(24) Mitragynine ---------- (11-2015)

(25) 7-Hydroxymitragynine---- ---------- ----------(11-2015)

(d) **Hallucinogenic substances:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following

hallucinogenic substance, or which contains any of its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation (for purposes of this paragraph only, the term "isomer" includes the optical, position and geometric isomers):

(1) alpha-ethyltryptamine ---------- 7249-(12-1993)

Some trade or other names: etryptamine; Monase; alpha-ethyl-1H-indole-3-ethanamine; 3-(2-aminobutyl)indole; alpha-ET; and AET.

(2) 4-bromo-2,5-dimethoxy-amphetamine ---------- 7391*

Some trade or other names: 4-bromo-2,5-dimethoxy-alpha-methylphenethylamine; 4-bromo-2,5-DMA.

(3) 4-bromo-2,5-dimethoxyphenethylamine ---------- 7392-(8-1995)

Some trade or other names: 2-(4-bromo-2,5-dimethoxyphenyl)-1 aminoethane; alpha-desmethyl DOB; 2C-B, Nexus.

(4) 2,5-dimethoxyamphetamine ---------- 7396*

Some trade or other names: 2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA.

(5) 2,5-dimethoxy-4-ethylamphetamine ---------- 7399-(3-1988)

Some trade or other names: DOET.

(6) 2,5-dimethoxy-4-(n)-propylthiophenethylamine ---------- 7348-(1-2005)

Some trade or other names: 2C-T-7.

(7) 4-methoxyamphetamine ---------- 7411*

Some trade or other names: 4-methoxy-alpha- methylphenethylamine; paramethoxyamphetamine; PMA.

(8) 5-methoxy-3,4-methylenedioxy-amphetamine ---------- 7401*

(9) 4-methyl-2,5-dimethoxyamphetamine ---------- 7395*

Some trade and other names: 4-methyl-2,5-dimethoxy-alphamethylphenethylamine; "DOM"; and "STP".

(10) 3,4-methylenedioxy amphetamine ---------- 7400*

(11) 3,4-methylenedioxymethamphetamine ---------- 7405-(10-1985)

Some trade or other names: MDMA)

(12) 3,4-methylenedioxy-N-ethylamphetamine ---------- 7404-(6-1990)

Some trade or other names: N- ethy-alpha-methyl-3,4 (methylenedioxy) phenethylamine, N-ethyl MDA; MDE; MDEA.

(13) N-hydroxy-3,4-methylenedioxyamphetamine ---------- 7402-(6-1990)

Some trade or other names: N-hydroxy-alpha-methyl-3,4(methylenedioxy) phenethylamine; N-hydroxy MDA

(14) 3,4,5-trimethoxy amphetamine ---------- 7390*

(15) 5-methoxy-n,n-dimethyltryptamine 5-MeO-DMT ---------- 7431*(1-2011)

(16) alpha-methyltryptamine ---------- 7432-(7-2005)

Some trade or other names: AMT

(17) Bufotenine ---------- 7433*

Some trade and other names: 3-(beta-Dimethylaminoethyl)-5-hydroxyindole; 3-(2-dimethylaminoethyl)-5-indolol; N,N-dimethylserotonin; 5-hydroxy-N,N-dimethyltryptamine; mappine.

(18) Diethyltryptamine ---------- 7434*

Some trade or other names: N,N-Diethyltryptamine;DET.

(19) Dimethyltryptamine ---------- 7435*

Some trade or other names: DMT

(20) 5-methoxy-N,N-diisopropyltryptamine ---------- 7439-(7-2005)

Some trade or other names: 5-MeO-DIPT.

(21) Ibogaine ---------- 7260*

Some trade and other names: 7-Ethyl-6,6 beta; 7,8,9,10,12,13-octahydro-2-methoxy-6,9-methano-5H-pyrido [1',2': 1,2] azepino [5,4-b] indole; Tabernanthe iboga.

(22) Lysergic acid diethylamide ---------- 7315*

(23) Mescaline ---------- 7381*

(24) Parahexyl ---------- 7374-(7-1983)

Some trade or other names: 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl.

(25) Peyote ---------- 7415*

Meaning all parts of the plant presently classified botanically as Lophophora williamsii Lemaire, whether growing or not; the seeds thereof; any extract from any part of such plant; and every compound, manufacture, salts, derivative, mixture or preparation of such plant, its seeds or extracts. (Interprets 21 USC 812 (c), Schedule I (c) (12)).

(26) N-ethyl-3-piperidyl benzilate ---------- 7482*

(27) N-methyl-3-piperidyl benzilate ---------- 7484*

(28) Psilocybin ---------- 7437*

(29) Psilocyn ---------- 7438*

(30) Ethylamine Analog of phencyclidine ---------- 7455*

Some trade or other names: N-ethyl-1-phenylcyclohexylamine, (phenylcyclohexyl)ethylamine; N-(1-phenylcyclohexyl)ethylamine; cyclohexamine; PCE.

(31) Pyrrolidine Analog of phencyclidine ---------- 7458*

Some trade or other names: 1-(1-phenylcyclohexyl)-pyrrolidine; PCPy; PHP

(32) Thiophene Analog of phencyclidine ---------- 7470*

Some trade or other names: 1-[1-(2-thienyl) cyclohexyl] Piperidine; 2-Thienyl analog of phencyclidine; TPCP; TCP.

(33) 1-[1-(2-Thienyl)cylcohexyl]pyrrolidine ---------- 7473-(9-1989)

Some other trade or other names: TCPy.

(34) N,N-Diallyl-5-Methoxytryptamine; ----------(6-2012)

Some trade or other names: 5-MeO DALT; 5-Methoxy-DALT

(35) 2-(4-chloro-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl)methyl]ethanamine; 25C-NBOMe ----------(5-2013)

(36) 2-(4-iodo-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25I-NBOMe ----------(8-2013)

(37) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine; 2C-E---------- 7509-(11-2013)

(38) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine; 2C-D---------- 7508-(11-2013)

(39) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine; 2C-C---------- 7519-(11-2013)

(40) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine; 2C-I---------- 7518-(11-2013)

(41) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-2 ---------- 7385-(11-2013)

(42) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine; 2C-T-4 ---------- 7532-(11-2013)

(43) 2-(2,5-Dimethoxyphenyl)ethanamine; 2C-H---------- 7517-(11-2013)

(44) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine; 2C-N---------- 7521-(11-2013)

(45) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine; 2C-P ---------- 7524-(11-2013)

(46) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine; 25B-NBOMe ----------(9-2018)

(47) 2-[[[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25B-NBOH ---------- (11-2018)

(48) 2-[[[2-(4-iodo-2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25I-NBOH------- (11-2018)

(49) 2-(4-ethyl-2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25E-NBOMe ----------(7-2019)

(50) 2-(2,5-dimethoxyphenyl)-N-[(2-methoxyphenyl) methyl]ethanamine; 25H-NBOMe ----------(7-2019)

(51) 2-[[[2-(4-chloro-2,5-dimethoxyphenyl)ethyl]amino]methyl]- phenol; 25C-NBOH ----------(7-2019)

(52) 2-[[[2-(2,5-dimethoxyphenyl)ethyl]amino]methyl]-phenol; 25H-NBOH----------(7-2019)

(53) 1-(4-methoxyphenyl)-N-methylpropan-2-amine ---------- 1245-(5-2022)

Some trade or other names: Para-methoxymethamphetamine; PMMA

(54) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one ---------- 7286

Some trade or other names: Methoxetamine; MXE

(e) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) gamma-hydroxybutyric acid [other name(s): GHB; gamma-hydroxybutyrate; 4-hydroxybutyrate; 4-hydroxydutanoic acid; sodium oxybate; sodium oxybutyrate], and its known precursors and analogs. Precursors include but are not limited to: gamma-butyrolactone ----------2010-(2-2001)

(2) Mecloqualone ---------- 2572*

(3) Methaqualone ---------- 2565*

(4) Benzodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Benzodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and benzene ring structure with a phenyl connected to the diazepine ring, with any substitution(s) or replacement(s) on the 1,4-diazepine or benzene ring, any substitution(s) on the phenyl ring, or any combination thereof. Benzodiazepine substances shall include but are not limited to:

(i) Bromazolam;

(ii) Clonazolam; ----------(4-2021)

(iii) Flualprazolam;----------(4-2021)

(iv) Flubromazepam; ----------(4-2021)

(v) Flubromazolam; ----------(4-2021)

(vi) Phenazepam;----------(6-2012)

(vii) Phenazolam [other name(s): Clobromazolam].

(5) Thienodiazepine substances, their isomers, esters, ethers, salts and salts of isomers, esters and ethers. Thienodiazepine substances includes any substance, not otherwise listed or excepted, and for which no exemption or approval is in effect under section 505 of the Federal Food, Drug, and Cosmetic Act [21 U.S.C. 355], that structurally has a fused 1,4-diazepine and thiophene ring structure with a phenyl connected to the 1,4-diazepine ring, with any substitution(s) or

replacement(s) on the 1,4-diazepine or thiophene ring, any substitution(s) on the phenyl ring, or any combination thereof. Thienodiazepine substances shall include but are not limited to:

(i) Etizolam ---------- (12-2014)

(f) **Stimulants**:

(1) Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(i) Cathinone ---------- 1235-(3-1988)

(ii) (±) CIS-4-Methylaminorex [(±)CIS-4,5-dihydro-4- methyl-5-phenyl-2-oxazolamine] ---------- 1590-(6-1990)

(iii) Fenethylline ---------- 1503-(9-1981)

(iv) N-Benzylpiperazine [other name(s): BZP, 1-Benzylpiperazine]---------- 7493-(1-2005)

~~Some trade or other name: BZP, 1-Benzylpiperazine~~

(v) N-ethylamphetamine ---------- 1475-(6-1982)

(vi) N-[1-(1-benzyl-4-piperidyl]-N-phenylpropanamide (benzylfentanyl), its optical isomers, salts and salts of isomers ---------- 9818-(2-1986)

(vii) N-[1-(2-thienyl)methyl-4-piperidyl)-N-phenylpropan-mide (thenylfentanyl), its optical isomers, salts and salts of isomers ---------- 9834-(2-1986)

(viii) N,N-Dimethylamphetamine [other name(s): N,N,Alpha-trimethylbenzeneethanamine; N,N,Alpha-trimethylphenethylamine], its salts, optical isomers, and salts of optical isomers ---------- 1480-(2-1989)

(ix) Methcathinone [other name(s):~~(some~~ 2-Methylamine-Proprophenone, alpha (methylamino)- Proprophenone, 2 (methylamino)-1-phenylpropan-1-one, alpha-N-Methylaminopropiophenone, monomethylpropion, ephedrone, N-methylcathinone, methycathinone, AL-464, AL-422, AL-463 and UR-1431], its salts, optical isomers and salts of optical isomers ---------- 1237-(12-1993)

(x) Aminorex [other name(s): aminoraphen, 2-amino-5 phenyl-2-oxazoline, or 4,5 dihyrdo-5-phenyl-2-oxazolamine], its salts, optical isomers, and salts of optical isomers ---------- 1585-(12-1993)

(xi) 4,4′-Dimethylaminorex ~~–~~[other name(s): ~~some~~ 4,4′-DMAR, 4,5-dihydro-4-methyl-5-(4-methylphenyl)-2-oxazolamine, or 4-methyl-5-(4-methylphenyl)-4,5-dihydro-1,3-oxazol-2-amine] ---------- 1595-(5-2022)

(xii) Amineptine ---------- 1219

(xiii) Mesocarb ---------- 1227

(xiv) Methyl-N-ethylcathinone (MEC)----------(6-2014)

(xv) Methiopropamine. [other name(s): N-methyl-1-(thiophen-2-yl)propan-2-amine] ---------- 1478

(2) Any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of the following substances' analogs, salts, isomers, and salts of isomers when the existence of the analogs, salts, isomers, and salts of isomers is possible within the specific chemical designation, with the following chemical structure is included in Schedule I:

(i) 4-Methylmethcathinone (Mephedrone) ---------- 1248-(3-2011)

(ii) Methylenedioxypyrovalerone (MDPV) ---------- (3-2011)

(iii) 3,4-Methylenedioxy-N-methylcathinone (Methylone) ---------- 7540-(3-2011)

(iv) 4-Methoxymethcathinone ---------- (3-2011)

(v) 3-Fluoromethcathinone ---------- (3-2011)

(vi) 4-Fluoromethcathinone---------- (3-2011)

(vii) 1-(1,3-benzodioxol-5-yl)-2-methylamino)butan-1-one-(Butylone) ---------- 7541-(11-2014)

(viii) Alpha-Pyrrolidinopentiophenone (Alpha-PVP) ---------- 7545-(11-2015)

(ix) 4-methyl-N-ethylcathinone (4-MEC) ---------- 1249-(9-2018)

(x) 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) ---------- 7498-(9-2018)

(xi) 2-(methylamino)-1-phenylpentan-1-one (Pentedrone) ---------- 1246-(9-2018)

(xii) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (Pentylone; bk-MBDP) ---------- 7542-(9-2018)

(xiii) 4-fluoro-N-methylcathinone (4-FMC, Flephedrone) ---------- 1238-(9-2018)

(xiv) 3-fluoro-N-methylcathinone (3-FMC) ---------- 1233-(9-2018)

(xv) 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (Naphyrone) ---------- 1258-(9-2018)

(xvi) Alpha-pyrrolidinobutiophenone ([Alpha]-PBP) ---------- 7546-(9-2018)

(xvii)3-methylmethcathinone (3–MMC) ---------- 1259

~~(xvii)~~(xviii) ---------- A compound, unless listed in another schedule or a legend drug, that is structurally derived from 2-Amino-phenyl-1-propanone by modification or by substitution: ---------- (3-2012)

(A) In the phenyl ring to any extent with alkyl, alkoxy, alkylenedioxy, haloalkyl or halide substituents, whether or not further substituted in the phenyl ring by one (1) or more other univalent substituents;

(B) At the 3-position with an alkyl substituent; or

(C) At the nitrogen atom with alkyl or dialkyl groups, or by inclusion of the nitrogen atom in a cyclic structure.

~~(xviii)~~(xix) ---------- 1
-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one (N-Ethylpentylone)--7543-(7-2019)

~~(xix)~~(xx) ---------- 1
-(1,3-benzodioxol-5-yl)-2-(ethylamino)propan-1-one (Ethylone)----------7547-(4-2021)

~~(xx)~~(xxi) ---------- 1
-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (Eutylone) ----------7549-(4-2021)

~~(xxi)~~(xxii) ---------- 2
-(ethylamino)-1-phenylhexan-1-one [other name(s): (N-Ethylhexedrone ; Alpha-Ethylaminohexanophenone)] ---------- 7246

~~(xxii)~~(xxiii) ----------
1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (Alpha-Pyrrolidinohexanophenone ; Alpha-PHP)]---------- 7544

~~(xxiii)~~(xxiv) ----------
2-(ethylamino)-1-(4-methylphenyl)pentan-1-one [other name(s): (4-Methyl-alpha-ethylaminopentiophenone ; 4-MEAP)]---------- 7245

~~(xxiv)~~(xxv) ----------
1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one [other name(s): (4′-Methyl-alpha-pyrrolidinohexiophenone ; MPHP)] ---------- 7446

~~(xxv)~~(xxvi) ---------- 1
-phenyl-2-(pyrrolidin-1-yl)heptan-1-one [other name(s): (Alpha-Pyrrolidinoheptaphenone ; PV8)] ---------- 7548

~~(xxvi)~~(xxvii) ----------
1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one [other name(s): (4′-Chloro-alpha-pyrrolidinovalerophenone ; 4-chloro-alpha-PVP)] ---------- 7443

~~(xxvii)~~(xxviii) ----------
4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one [other name(s): alpha-PiHP, Alpha-Pyrrolidinoisohexanophenone] ---------- 7551

SCHEDULE II

(a) Schedule II shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the Controlled Substances Code Number set forth opposite it.

(b) **Narcotic Drugs:** Substances, vegetable origin or chemical synthesis. Unless specifically excepted or unless listed in another schedule, any of the following substances whether produced directly or indirectly by extraction from substances of vegetable origin, or independently by means of chemical synthesis, or by combination of extraction and chemical synthesis:

(1) Opium and opiate, and any salt, compound, derivative, or preparation of opium or opiate excluding apomorphine, thebaine-derived butorphanol, dextrorphan,

nalbuphine, naldemedine, nalmefene, naloxegol, naloxone, 6β-naltrexol, naltrexone and samidorphan, and their respective salts, but including the following:

(i) Raw opium ---------- 9600*

(ii) Opium extracts ---------- 9610*

(iii) Opium fluid extracts ---------- 9620*

(iv) Powdered opium ---------- 9639*

(v) Granulated opium ---------- 9640*

(vi) Tincture of opium ---------- 9630*

(vii) Codeine ---------- 9050*

(viii) Dihydroetorphine ---------- 9334*

(ix) Ethylmorphine ---------- 9190*

(x) Etorphine hydrochloride ---------- 9059*

(xi) Hydrocodone ---------- 9193*

(xii) Hydromorphone ---------- 9150*

(xiii) Metopon ---------- 9260*

(xiv) Morphine ---------- 9300*

(xv) Oripavine ---------- 9330*(9-2007)

(xvi) Oxycodone ---------- 9143*

(xvii)Oxymorphone ---------- 9652*

(xviii) Thebaine ---------- 9333*

(xix) Tapentadol ---------- 9780-(5-2009)

(xx) Noroxymorphone ---------- 9668-(4-2021)

(2) Any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of the substances referred to in paragraph (b) (1) of this section, except that these substances shall not include the isoquinoline alkaloids of opium.*

(3) Opium poppy and poppy straw.*

(4) Coca leaves (9040) and any salt, compound, derivative, or preparation of coca leaves, (including cocaine (9041) and ecgonine (9180) and their salts, isomers, derivatives and salts of isomers and derivatives), and any salt, compound, derivative, or preparation thereof which is chemically equivalent or identical with any of these substances, except that the substances shall not include: ---------- *

(i) Decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine ; ---------- *

(ii) [^{123}I]ioflupane; or

(iii) [^{18}F]FP–CIT.

(5) Concentrate or poppy straw (the crude extract of poppy straw in either liquid, solid or powder form which contains the phenanthrene alkaloids of the opium poppy), ---------- 9670.*

(c) **Opiates: (Narcotic Drugs)** Unless specifically excepted or unless in another schedule, any of the following opiates, including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers whenever the existence of such isomers, esters, ethers, and salts is possible within the specific chemical designations:

(1) Alfentanil ---------- 9737-(2-1987)

(2) Alphaprodine ---------- 9010*

(3) Anileridine ---------- 9020*

(4) Bezitramide ---------- 9800*

(5) Bulk Dextropropoxyphene (non-dosage forms) ---------- 9273-(9-1981)

(6) Carfentanil ---------- 9743-(9-1988)

(7) Dihydrocodeine ---------- 9120*

(8) Diphenoxylate ---------- 9170*

(9) Fentanyl ---------- 9801*

(10) Isomethadone ---------- 9226*

(11) Levo-alphacetylmethadol (LAAM) ---------- 9648-(12-1993)

(12) Levomethorphan ---------- 9210*

(13) Levorphanol ---------- 9220*

(14) Metazocine ---------- 9240*

(15) Methadone ---------- 9250*

(16) Methadone-Intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane ---------- 9254*

(17) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid ---------- 9802*

(18) Pethidine (Meperidine) ---------- 9230*

(19) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine ---------- 9232*

(20) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate ---------- 9233*

(21) Pethidine-Intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid ---------- 9234*

(22) Phenazocine ---------- 9715*

(23) Piminodine ---------- 9730*

(24) Racemethorphan ---------- 9732*

(25) Racemorphan ---------- 9733*

(26) Remifentanil ---------- 9739-(11-1996)

(27) Sufentanil ---------- 9740-(9-1981)

(28) Thiafentanil ---------- 9729-(4-2021)

(29) Oliceridine ---------- 9245-(5-2022)

(30) Tianeptine ---------- (5-2022)

(d) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system:

(1) Amphetamine, its salts, optical isomers, and salts of its optical isomers ---------- 1100*

(2) Methamphetamine, its salts, isomers, and salts of its isomers ---------- 1105*

(3) Lisdexamefetamine ---------- 1205*(7-2007)

(4) Phenmetrazine and its salts ---------- 1631*

(5) Methylphenidate ---------- 1724*

(e) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Amobarbital ---------- 2125*

(2) Glutethimide ---------- 2550-(2-1991)

(3) Pentobarbital ---------- 2270*

(4) Phencyclidine ---------- 7471*

(5) Secobarbital ---------- 2315*

(f) **Hallucinogenic Substances:**

(1) Nabilone ---------- 7379-(11-1987)

[Other name(s) for nabilone: (±)-trans-3-(1,1-dimethylheptyl)-6,6a,7,8,10,10a-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b,d]pyran-9-one].

(2) Dronabinol in an oral solution in a drug product approved for marketing by the U.S. Food and Drug Administration; [(-)-delta-9-trans-tetrahydrocannabinol(delta-9-THC)]. ---------- 7365-(7-2019)

(g) **Immediate Precursor**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:

(1) Immediate precursor to Amphetamine and Methamphetamine:

(i) Phenylacetone ---------- 8501-(3-1980)

Some trade or other names: phenyl-2-propanone; P2P; benzyl methyl Ketone; methyl benzyl Ketone.

(2) Immediate precursor to Phencyclidine (PCP):

(i) 1-phenylcyclohexylamine ---------- 7460*

(ii) 1-piperidinocyclohexanecarbonitrile (PCC) ---------- 8603*

(3) Immediate precursor to Fentanyl:

(i) 4-anilino-N-phenethylpiperidine (ANPP) ---------- 8333*(8-2010)

(ii) N-phenyl-N-(piperidin-4-yl)propionamide (norfentanyl) ---------- 8366-(4-2021)

SCHEDULE III

(a) Schedule III shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Stimulants:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Those compounds, mixtures, or preparations in dosage unit form containing any stimulant substances listed in Schedule II which compounds, mixtures, or preparations were listed on August 25, 1971, as excepted compounds under Section 308.32, and any other drug of the quantitative composition shown in that list for those drugs or which is the same except that it contains a lesser quantity of controlled substances ---------- 1405*

(2) Benzphetamine ---------- 1228*

(3) Chlorphentermine ---------- 1645*

(4) Clortermine ---------- 1647*

(5) Phendimetrazine ---------- 1615*

(c) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system:

(1) Any compound, mixture, or preparation containing:

(i) Amobarbital ---------- 2126*

(ii) Secobarbital ---------- 2316*

(iii) Pentobarbital ---------- 2271*

(iv) Embutramide ---------- 2020*(9-2006)

or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.

(2) Any suppository dosage form containing:

(i) Amobarbital ---------- 2126*

(ii) Secobarbital ---------- 2316*

(iii) Pentobarbital ---------- 2271*

or any salt of any of these drugs and approved by the Food and Drug Administration for marketing only as a suppository.

(3) Any substance which contains any quantity of a derivative of barbituric acid or any salt thereof ---------- 2100*

(4) Chlorhexadol ---------- 2510*

(5) Any drug product containing gamma hydroxybutyric acid, including its salts, isomers, and salts of isomers, for which an application is approved under section 505 of the Federal Food, Drug, and Cosmetic Act ---------- 2012-(2-2001)

(6) Ketamine. its salts, isomers, and salts of isomers ---------- 7285-(7-1999)

Some other names for Ketamine: (+-)-2-(2-Chlorophenyl)-2-(Methylamino)-Cyclohexanone.

(7) Lysergic acid ---------- 7300*

(8) Lysergic acid amide ---------- 7310*

(9) Methyprylon ---------- 2575*

(10) Sulfondiethylmethane ---------- 2600*

(11) Sulfonethylmethane ---------- 2605*

(12) Sulfonmethane ---------- 2610*

(13) Tiletamine and zolazepam or any salt thereof ---------- 7295-(3-1988)

Some trade or other name for a tiletamine- zolazepam combination product: Telazol.

Some trade or other names for tiletamine: 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.

Some trade or other names for zolazepam: 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethyl-pyrazolo-[3,4-e]-[1,4]-diazepin-7(1-H)-one; flupyrazapon.

(14) Perampanel ---------- 2261-(11-2013)

(15) Xylazine and any material, compound, mixture, or preparation which contains any quantity of xylazine, including its salts, isomers, and salts of isomers

whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation, except in the following uses:

(i) Dispensing, prescribing, or administering, to an animal, a drug containing xylazine that has been approved by the United States Secretary of Health and Human Services under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b);

(ii) Dispensing, prescribing, or administering xylazine to an animal that is permissible under section 512 (a)(4) of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(a)(4));

(iii) Possessing a drug containing xylazine, as described in this section (15), for animal use :

(A) By a licensed pharmacist or licensed veterinarian ; or

(B) Pursuant to a valid prescription from a licensed veterinarian ;

(iv) Possessing, manufacturing, distributing, or using xylazine as an active pharmaceutical ingredient for manufacturing an animal drug either:

(A) Approved under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b); or

(B) Issued an investigation use exemption under section 512 of the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 360b(j));

(v) Manufacturing, distributing, or using a xylazine bulk chemical for pharmaceutical compounding by a licensed pharmacist or veterinarian; or

(vi) Another use approved or permissible under the Federal Food, Drug and Cosmetic Act (21 U.S.C. § 301, et seq.) or under 21 CFR Part 530, Subpart B.

(d) Nalorphine ---------- 9400*

(e) **Narcotic drugs:** Unless specifically excepted or unless listed in another schedule:

(1) Any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(i) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with an equal or greater quantity of an isoquinoline alkaloid of opium ---------- 9803*

(ii) Not more than 1.8 grams of codeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ---------- 9804*

(iii) Not more than 1.8 grams of dihydrocodeine per 100 milliliters or not more than 90 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ---------- 9807*

(iv) Not more than 300 milligrams of ethylmorphine per 100 milliliters or not more than 15 milligrams per dosage unit, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ---------- 9808*

(v) Not more than 500 milligrams of opium per 100 milliliters or per 100 grams or not more than 25 milligrams per dosage unit, with one or more active nonnarcotic ingredients in recognized therapeutic amounts ---------- 9809*

(vi) Not more than 50 milligrams of morphine per 100 milliliters or per 100 grams, with one or more active, nonnarcotic ingredients in recognized therapeutic amounts ---------- 9810*

(2) Any material, compound, mixture, or preparation containing any of the following narcotic drugs or their salts, as set forth below:

(i) Buprenorphine ---------- 9064-(6-1985) (10-02 Transfer)

(ii) Reserved

(f) Anabolic Steroids: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts of isomers is possible within the specific chemical designation: ---------- 4000

(1) Boldenone;----------(9-1991)

(2) Boldione;----------(1-2010)

(3) Chlorotestosterone (4-chlortestosterone); ----------(9-1991)

(4) Clostebol; ----------(9-1991)

(5) Dehydrochlormethyltestosterone; ----------(9-1991)

(6) Desoxymethyltestosterone----------(1-2010)

(7) Dihydrotestosterone (4-dihydrotestosterone); ----------(9-1991)

(8) Drostanolone;----------(9-1991)

(9) Ethylestrenol;----------(9-1991)

(10) Fluoxymesterone; ----------(9-1991)

(11) Formebulone (formebolone); ----------(9-1991)

(12) Mesterolone; ----------(9-1991)

(13) Methandienone, also known as Methandrostenolone; ----------(9-1991)

(14) Methandranone;----------(9-1991)

(15) Methandriol;----------(9-1991)

(16) Methenolone;----------(9-1991)

(17) Methyltestosterone; ----------(9-1991)

(18) Mibolerone; ----------(9-1991)

(19) Nandrolone; ----------(9-1991)

(20) 19-Nor-4,9(10)-Androstadienedione ----------(1-2010)

(21) Norethandrolone; ----------(9-1991)

(22) Oxandrolone; ----------(9-1991)

(23) Oxymesterone; ----------(9-1991)

(24) Oxymetholone; ----------(9-1991)

(25) Stanolone; ----------(9-1991)

(26) Stanozolol; ----------(9-1991)

(27) Testolactone; ----------(9-1991)

(28) Testosterone; ----------(9-1991)

(29) Trenbolone ----------(9-1991)

(30) Prostanozol ----------(8-2012)

(31) Methasterone ----------(8-2012); and

(32) Any salt, ester, or isomer of a drug or substance described or list in this paragraph, if that salt, ester, or isomer promotes muscle growth. ----------(9-1991)

(g) Exempt anabolic steroid products: Compounds, mixtures, or preparations that contain an anabolic steroid that have been exempted by the Secretary:

	NDC Number
(1) Andro-Estro 90-4	0536-1605
(2) Androgyn L.A	0456-1005
(3) Component E-H in Process Pellets	Ivy Labs Inc.
(4) Component E-H in Process Granulation	Ivy Labs Inc
(5) Component TE-S in process Granulation	Ivy Labs Inc
(6) Component TE-S in process Pellets	Ivy Labs Inc
(7) depANDROGYN	0456-1020
(8) Depo-Testadiol	0009-0253
(9) DEPO-T.E	52765-257
(10) depTESTROGEN	51698-257
(11) Duomone	52047-360
(12) DUO-SPAN II	0684-0102
(13) DURATESTRIN	43797-016

(14) Essian ---------- Pharmaceutics
(15) Essian H.S ---------- Pharmaceutics
(16) Esterified Estrogens & Methyltestosterone, USP (0.625 mg/1.25mg) ---------- Interpharm
(17) Esterified Estrogens & Methyltestosterone, USP (1.25mg/2.5mg) ---------- Interpharm
(18) Esterified Estrogens & Methyltestosterone (0.625mg/1.25mg) Tablet---------- ANDAPharm
(19) Esterified Estrogens & Methyltestosterone (1.25mg/2.5mg) Tablet---------- ANDAPharm
(20) Estratest ---------- 0032-1026
(21) Estratest HS ---------- 0032-1023
(22) Menogen ---------- 59243-570
(23) Menogen HS ---------- 59243-560
(24) Methyltestosterone & Esterified Estrogens (2.5mg/1.25Mg) ---------- Lannett Co
(25) Methyltestosterone & Esterified Estrogens (Half Strength) (1.25mg/0.625mg) ----- Lannett Co
(26) PAN ESTRA TEST ---------- 0525-0175
(27) Premarin with Methyltestosterone ---------- 0046-0879
(28) Premarin with Methyltestosterone ---------- 0046-0878
(29) Syntest D.S ---------- 66576-231
(30) Stntest H.S---------- 66576-230
(31) Synovex H in process bulk pellets ---------- Syntex Animal
(32) Synovex H in process granulation ---------- Syntex Animal
(33) Synovex Plus in process granulation ---------- Fort Dodge
(34) Synovex Plus in process bulk pellets ---------- Fort Dodge
(35) TEST-ESTRO Cypionates ---------- 0536-9470
(36) Testoderm with Adhesive 4mg/d---------- Alza Corp
(37) Testoderm 4mg/d ---------- 17314-4608
(38) Testoderm 6mg/d ---------- 17314-4609
(39) Testoderm with Adhesive 6mg/d---------- 17314-2836
(40) Testoderm in process film---------- Alza Corp
(41) Testoderm with Adhesive in process film ---------- Alza Corp
(42) Testosterone Cypionate/Estradiol Cypionate injection ---------- 54274-530
(43) Testosterone Cypionate/Estradiol Cypionate injection ---------- 0182-3069
(44) Testosterone Cyp 50 Estradiol Cyp 2 ---------- 0814-7737
(45) Testosterone Cypionate/Estradiol Cypionate injection ---------- 0364-6611
(46) Testosterone Cypionate/Estradiol Cypionate injection ---------- 0402-0257

(47) Testosterone Enanthate/Estradiol Valerate injection ---------- 0182-3073

(48) Testosterone Enanthate/Estradiol Valerate injection ---------- 0364-6618

(49) Testosterone Enanthate/Estradiol Valerate injection ---------- 0402-0360

(50) Testosterone Ophthalmic Solution ---------- Allergan

(51) Tilapia Sex Reversal Feed (investigational) ---------- Ranger, Inc

(h) Veterinary Anabolic Steroid Implant Products: Anabolic steroid products expressly intended for administration through implants in cattle or other nonhuman species exempted by the Secretary.

NDC/DIN

(1) Component E-H ---------- 021641-002

(2) Component E-H ---------- 01968327

(3) Component TE-S ---------- 021641-004

(4) Component T-H ---------- 0211641-006

(5) Component T-S ---------- 0211641-005

(6) F-TO ---------- 00093351

(7) Finaplix-H ---------- 12799-807-10

(8) Finaplix-S ---------- 12799-807-07

(9) Heifer-old ---------- Boehringer

(10) Heifer-old ---------- Ingelheim

(11) Heifer-old ---------- Ivy Lab.

(12) Implus-H ---------- 0009-0434-01

(13) Implus-H ---------- 06-0434-01

01968327

(14) Masculinizing Feed for Fish (Invesitigational) ---------- Rangen,Inc.

(15) Revalor-G ---------- 12799-811

(16) Revalor-H ---------- 12799-810

(17) Revalor-S ---------- 12799-809

(18) Synovex H ---------- 0856-3901

(19) Synovex H ---------- Syntex

(20) Synovex Plus ---------- 0856-3904

(21) Tilapia Sex Reversal Feed (investigational) ---------- Zeigier Bros.

If veterinary products that are granted exempted status are subsequently distributed with the intent that they be used in humans, the distribution would be subject to the criminal sanctions of the CSA despite the drugs' exempted status.

(i) **Hallucinogenic substances**:

(1) Dronabinol (synthetic) in sesame oil and encapsulated in a soft gelatin capsule in a U.S. Food and Drug Administration approved drug product ---------- 7369-(11-1987)

[Some other names for dronabinol: (6a R-trans)-6a,7,8, 10a-tetrahydro-6, 6, 9-trimethyl-3-pentyl-6H-dibenzo [b,d] phyran-1-ol, or (-)-delta 9-(trans)-tetrahydrocannabinol]

SCHEDULE IV

(a) Schedule IV shall consist of the drugs and other substances, by whatever official name, common or usual name, chemical name or brand name designated, listed in this section. Each drug or substance has been assigned the DEA Controlled Substances Code Number set forth opposite it.

(b) **Narcotic drugs**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation containing any of the following narcotic drugs, or their salts calculated as the free anhydrous base or alkaloid, in limited quantities as set forth below:

(1) Not more than 1 milligram of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit---------- 9167*

(2) Dextro propoxyphene (alpha-(+)-4-dimethylamino- 1,2-diphenyl-3-methyl-2-propionoxybutane) ---------- 9278-(11-1987)

(c) **Depressants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Alprazolam ---------- 2882-(6-1982)

(2) Barbital ---------- 2145*

(3) Bromazepam ---------- 2748-(1-1985)

(4) Camazepam ---------- 2749-(1-1985)

(5) Chloral betaine ----------2460*

(6) Chloral hydrate ---------- 2465*

(7) Chlordiazepoxide ---------- 2744*

(8) Clobazam ---------- 2751-(1-1985)

(9) Clonazepam ---------- 2737*

(10) Clorazepate ---------- 2768*

(11) Clotiazepam ---------- 2752-(1-1985)

(12) Cloxazolam ---------- 2753-(1-1985)

(13) Delorazepam ---------- 2754-(1-1985)

(14) Diazepam ---------- 2765*
(15) Dichloralphenazone ---------- 2467-(10-2002)
(16) Estazolam ---------- 2756-(1-1985)
(17) Ethchlorvynol ---------- 2540*
(18) Ethinamate ---------- 2545*
(19) Ethyl loflazepate ---------- 2758-(1-1985)
(20) Fludiazepam ---------- 2759-(1-1985)
(21) Flunitrazepam ---------- 2763-(1-1985)
(22) Flurazepam ---------- 2767*
(23) Fospropofol---------- 2138-(11-2009)
(24) Halazepam ---------- 2762-(6-1982)
(25) Haloxazolam ---------- 2771-(1-1985)
(26) Ketazolam ---------- 2772-(1-1985)
(27) Loprazolam ---------- 2773-(1-1985)
(28) Lorazepam ---------- 2885*
(29) Lormetazepam ---------- 2774-(1-1985)
(30) Mebutamate ---------- 2800*
(31) Medazepam ---------- 2836-(1-1985)
(32) Meprobamate ---------- 2820*
(33) Methohexital ---------- 2264*
(34) Methylphenobarbital (mephorbarbital) ---------- 2250*
(35) Midazolam ---------- 2884-(1-1985)
(36) Nimetazepam ---------- 2837-(1-1985)
(37) Nitrazepam ---------- 2834-(1-1985)
(38) Nordiazepam ---------- 2838-(1-1985)
(39) Oxazepam ---------- 2835*
(40) Oxazolam ---------- 2839*
(41) Paraldehyde ---------- 2585*
(42) Petrichloral ---------- 2591*
(43) Phenobarbital ---------- 2285*
(44) Pinazepam ---------- 2883-(1-1985)
(45) Prazepam ---------- 2764*
(46) Quazepam ---------- 2881-(11-1986)

(47) Temazepam ---------- 2925-(9-1981)
(48) Tetrazepam ---------- 2886-(1-1985)
(49) Triazolam ---------- 2887-(7-1983)
(50) Zaleplon ---------- 2781-(9-1999)
(51) Zolpidem ---------- 2783-(12-1993)
(52) Zopiclone ---------- 2784-(1-2006)
(53) Alfaxalone ---------- 2731-(2-2014)
(54) Carisoprodol ---------- 8192-(4-1997)
(55) Tramadol ---------- 9752-(8-2007)
(56) Suvorexant ---------- 2223-(8-2014)
(57) Brexanolone ---------- 2400-(4-2021)
(58) Lemborexant ---------- 2245-(4-2021)
(59) Remimazolam ---------- 2846-(5-2022)
(60) Daridorexant ---------- 2410
(61) Zuranolone ---------- 2420

(d) **Stimulants**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers (whether optical, position, or geometric), and salts of such isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:

(1) Cathine ((+)-Norpseudoephedrine)~~Norpseudeophedrine~~ ---------- 1230-(3-1988)
(2) Diethylpropion ---------- 1610*
(3) Fencamfamin ---------- 1760-(3-1988)
(4) Fenproporex ---------- 1575-(3-1988)
(5) Lorcaserin ---------- 1625-(6-2013)
(6) Mazindol ---------- 1605-(6-1982)
(7) Mefenorex ---------- 1580-(3-1988)
(8) Modafinil---------- 1680-(1-1999)
(9) Pemoline (including organometallic complexes and chelates thereof) ---------- 1530*
(10) Phentermine ---------- 1640*
(11) Pipradrol ---------- 1750-(9-1981)
(12) Serdexmethylphenidate ---------- 1729
(13) Sibutramine ---------- 1675-(2-1998)

(14) Solriamfetol ---------- 1650-(4-2021)

(15) SPA ((-)-1-dimethylamino-1,2,diphenylethane) ---------- 1635-(9-1981)

(e) **Other substances**: Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances, including its salts; isomers whether optical, position, or geometric), and salts of such isomers, whenever the existence of such salts, isomers, and salts of isomers is possible:

(1) Pentazocine ---------- 9709-(4-1979)

(2) Butorphanol ---------- 9720-(4-1997)

(3) Nalbuphine ---------- (4-1997)

(4) Eluxadoline ---------- 9725-(4-2017)

SCHEDULE V

(a) Schedule V shall consist of the drugs and other substances by whatever official name, common or usual name, chemical name, or brand name designated, listed in this section.

(b) **Narcotic Drugs:** Unless specifically excepted or unless listed in another schedule, any material, compound, mixture or preparation containing any of the following narcotic drugs and their salts, as set forth below.

Reserved

(c) **Narcotic drugs containing nonnarcotic active medicinal ingredients.** Any compound, mixture, or preparation containing any of the following limited quantities of narcotic drugs or salts thereof, which shall include one or more nonnarcotic active medicinal ingredients in sufficient proportion to confer upon the compound, mixture, or preparation valuable medicinal qualities other than those possessed by the narcotic drug alone:

(1) Not more than 200 milligrams of codeine per 100 milliliters or per 100 grams. ---------- *

(2) Not more than 100 milligrams of dihydrocodeine per 100 milliliters or per 100 grams. ---------- *

(3) Not more than 100 milligrams of ethylmorphine per 100 milliliters or per 100 grams. ---------- *

(4) Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit. ---------- *

(5) Not more than 100 milligrams of opium per 100 milliliters or per 100 grams. ---------- *

(6) Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit. ---------- *

(d) **Stimulants**: unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having stimulant effect on the central nervous system, including its salts, isomers and salts of isomers:

(1) Pyrovalerone ---------- 1485-(3-1988)

(2) Ephedrine:a -{-(Methylamino)ethyl}benzene-methanol; ---------- (10-1995)

a-{-(methylamino) ethyl}benzyl alcohol; 2-methylamino-1-phenyl-1-propanol; 1-phenyl-1-hydroxy-2-methylaminopropane; 1-phenyl-2-methylaminopropanol; a - hydroxy-b-methylaminopropylbenzene; a product which occurs in the Chinese herb Ma Huang (Ephedra vulgaris, Ephedra sinica Stapf., Ephedra equisetina Bunge, Gnetaceae) in several other Ephedra spp.

(3) Phenylpropanolamine ----------(7-2005)

(4) Pseudoephedrine ---------- (7-2005)

Pursuant to Ark. Code Ann. § 5-64-212 as amended in 2005, this Schedule V classification shall NOT apply to any ephedrine, phenylpropanolamine, or pseudoephedrine in liquid, liquid capsule, or liquid gel capsule form. However, sales limits mandated by statute shall apply to all products with ephedrine, phenylpropanolamine, or pseudoephedrine as a listed ingredient regardless of the dosage form.

(e) **Depressants:** Unless specifically exempted or excluded or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers:

(1) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic acid ---------- 2782-(1-2006)

(2) Lacosamide ---------- 2746-(5-2009)

(3) Brivaracetam ---------- 2710-(4-2017)

(4) Lasmiditan ---------- 2790-(4-2021)

(5) Cenobamate ---------- 2720-(4-2021)

(6) Ganaxolone ---------- 2401

(f) **Other substances**:

(1) None.

SCHEDULE VI ****

(a) In addition to any substance placed in Schedule VI by the Secretary of the Department of Health under § 5-64-214, any material, compound, mixture, or preparation, whether produced directly or indirectly from a substance of vegetable origin or independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, that contains any quantity of the following substances, or that contains any of their salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation, is included in Schedule VI:

(1) Marijuana ---------- **

(2) Tetrahydrocannabinols, unless the tetrahydrocannabinol is: ---------- **

(i) Contained in hemp-derived cannabidiol; ----------(6-2020)

(ii) Not more than three-tenths of one percent (0.3%) of delta-9 tetrahydrocannabinol in the hemp-derived cannabidiol on a dry weight basis as verified by a nationally accredited laboratory for quality, purity and accuracy standards; and----------(6-2020) ***

(iii) Not approved by the United States Food and Drug Administration for marketing as a medication; ----------(6-2020)

(3) A synthetic equivalent of:

(i) The substance contained in the Cannabis plant; or---------- **

(ii) The substance contained in the resinous extractives of the genus Cannabis; ---------- **

(4) Salvia divinorum or Salvinorin A, which includes all parts of the plant presently classified botanically as Salvia divinorum, whether growing or not, the seeds of the plant, any extract from any part of the plant, and every compound, manufacture, derivative, mixture, or preparation of the plant, its seeds, or its extracts, including salts, isomers, and salts of isomers when the existence of the salts, isomers, and salts of isomers is possible within the specific chemical designation; ---------- **

(5) Synthetic substances, derivatives, or their isomers in the chemical structural classes described below in subdivisions (a)(5)(i)-(a)(5)(x) of this section and also specific unclassified substances in subdivision (a)(5)(xi) of this section. Compounds of the structures described in this subdivision (a)(5), regardless of numerical designation of atomic positions, are included in this subdivision (a)(5). The synthetic substances, derivatives, or their isomers included in this subdivision (a)(5) are:

(i) Tetrahydrocannabinols:

(A) Tetrahydrocannabinols, including without limitation the following: ---------- **

a) Delta-1 cis or trans tetrahydrocannabinol [other name(s): Delta-9 cis or trans tetrahydrocannabinol], and its optical isomers; ---------- **

b) Delta-6 cis or trans tetrahydrocannabinol [other name(s): Delta-8 cis or trans tetrahydrocannabinol], and its optical isomers; ---------- **

c) Delta- 3,4 cis or trans tetrahydrocannabinol [other name(s): Delta-6a,10a cis or trans tetrahydrocannabinol], and its optical isomers ; ---------- **

d) Delta-10 cis or trans tetrahydrocannabinol, and its optical isomers ;---------- ***

e) Delta-8 tetrahydrocannabinol acetate ester; ---------- ***

f) Delta-9 tetrahydrocannabinol acetate ester; ---------- ***

g) Delta-6a,10a, tetrahydrocannabinol acetate ester;---------- ***

h) Delta-10 tetrahydrocannabinol acetate ester; and,---------- ***

i) A product derived from industrial hemp that was produced as a result of a synthetic chemical process that converted the industrial hemp or a substance contained in industrial hemp into Delta-8, Delta-9, Delta 6a,10a, or Delta-10 tetrahydrocannabinol including their respective acetate esters. ---------- ***

(B) Dronabinol in sesame oil and encapsulated in a soft gelatin capsule in a drug product approved by the United States Food and Drug Administration is not a tetrahydrocannabinol under this subdivision (a)(5)(i); ---------- **

(ii) Naphthoylindoles, or any compound structurally derived from 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ---------- **

(A) JWH-007, or 1-pentyl-2-methyl-3-(1-naphthoyl)indole; ---------- **

(B) JWH-015, or 1-Propyl-2-methyl-3-(1-naphthoyl)indole; ---------- **

(C) JWH-018, or 1-Propyl-3-(1-naphthoyl)indole; ----------

(D) JWH-019, or 1-Hexyl-3-(1-naphthoyl)indole; ---------- **

(E) JWH-073, or 1-Butyl-3-(1-naphthoyl)indole; ---------- **

(F) JWH-081, or 1-Pentyl-3-(4-methoxy-1-naphthoyl)indole; ---------- **

(G) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-naphthoyl)indole; ---------- **

(H) JWH-122, or 1-Pentyl-3-(4-methyl-1-naphthoyl)indole; ---------- **

(I) JWH-164, or 1-pentyl-3-(7-methoxy-1-naphthoyl)indole; ---------- **

(J) JWH-200, or 1-[2-(4-morpholiny)ethyl]-3-(1-naphthoyl) indole; ---------- **

(K) JWH-210, or 1-Pentyl-3-(4-ethyl-1-naphthoyl)indole; ---------- **

(L) JWH-398, or 1-Pentyl-3-(4-chloro-1-naphthoyl)indole; ---------- **

(M) AM-2201, or 1-(5-fluoropentyl)-3-(1-naphthoyl)indole; ---------- **

(N) MAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone; ---------- **

(O) EAM2201, or (1-(5-fluoropentyl)-1H-indol-3-yl)(4-ethyl-1-naphthalenyl)-methanone; and ---------- **

(P) THJ-2201, or [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone; ----------7024-(7-2019)

(iii) Naphthylmethylindoles, or any compound structurally derived from an H-indol-3-yl-(1-naphthyl) methane by substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,

1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation the following: ---------- **

(A) JWH-175, or 1-Pentyl-1H-indol-3-yl-(1-naphthyl)methane; and---------- **

(B) JWH-184, or 1-Pentyl-1H-3-yl-(4-methyl-1-naphthyl)methane; ---------- **

(iv) Naphthoylpyrroles, or any compound structurally derived from 3-(1-naphthoyl)pyrrole by substitution at the nitrogen atom of the pyrrole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the pyrrole ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-307, or (5-(2-fluorophenyl)-1-pentylpyrrol-3-yl)-naphthalen-1-ylmethanone; ---------- **

(v) Naphthylmethylindenes, or any compound structurally derived from 1-(1-napthylmethyl)indene with substitution at the 3-position of the indene ring by an alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indene ring to any extent and whether or not substituted in the naphthyl ring to any extent, including without limitation JWH-176, or E-1-[1-(1-Naphthalenylmethylene)-1H-inden-3-yl]pentane; ---------- **

(vi) Phenylacetylindoles, or any compound structurally derived from 3-phenylacetylindole by substitution at the nitrogen atom of the indole ring with alkyl, haloalkyl, alkenyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ---------- **

(A) JWH-201, or 2-(4-methoxyphenyl)-1-(1-pentylindol-3-yl)ethanone;---------- **

(B) JWH-203, or 1-Pentyl-3-(2-chlorophenylacetyl)indole; ---------- **

(C) JWH-250, or 1-Pentyl-3-(2-methoxyphenylacetyl)indole; ---------- **

(D) JWH-251, or 1-Pentyl-3-(2-methylphenylacetyl)indole; and ---------- **

(E) RCS-8, or 1-(2-cyclohexylethyl)-3-(2- methoxyphenylacetyl)indole; ---------- **

(vii) Cyclohexylphenols, or any compound structurally derived from 2-(3-hydroxycyclohexyl)phenol by substitution at the 5-position of the phenolic ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, or 2-(4-morpholinyl)ethyl group, whether or not substituted in the cyclohexyl ring to any extent, including without limitation the following: ---------- **

(A) CP 47,497 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; ---------- **

(B) Cannabicyclohexanol or CP 47,497 C8 homologue, or 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol; and---------- **

(C) CP 55,940, or 5-(1,1-dimethylheptyl)-2-[(1R,2R)-5-hydroxy-2-(3-hydroxypropyl)cyclohexyl]-phenol; ---------- **

(viii) Benzoylindoles, or any compound structurally derived from a 3-(benzoyl)indole structure with substitution at the nitrogen atom of the indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent, including without limitation the following: ---------- **

(A) AM-694, or 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole; ---------- **

(B) RCS-4, or 1-Pentyl-3-(4-methoxybenzoyl)indole; ---------- **

(C) WIN-48,098 or Pravadoline, or (4-Methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y]methanone; ---------- **

(D) AM-2233, or 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole; and ---------- **

(E) RCS-4 (C4 homologue) or (4-methoxyphenyl)(1-butyl-1H-indol-3-yl)-methanone; ---------- **

(ix) Adamantoylindoles, or Adamantoylindazoles, including Adamantyl Carboxamide Indoles and Adamantyl Carboxamide Indazoles, or any compound structurally derived from 3-(1-adamantoyl) indole, 3-(1-adamantoyl) indazole, or 3-(2-adamantoyl)indole by substitution at a nitrogen atom of the indole or indazole ring with alkyl, haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl,cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole or indazole ring to any extent and whether or not substituted in the adamantly ring to any extent, including without limitation the following: ---------- **

(A) AM-1248, or 1-adamantyl-[1-[(1-methylpiperidin-2-yl)methyl]indol-3-yl]methanone; ---------- **

(B) AB-001, or 1-adamantyl-(1-pentylindol-3-yl)methanone; ---------- **

(C) JWH-018 adamantyl carboxamide, or 1-pentyl-N-tricyclo[3.3.1.13,7]dec-1-yl-1H-indole-3-carboxamide [other name(s): 2NE1, moved in Schedule VI in 2020] ---------- **

(D) AKB-48, or N-(1-adamantyl)-pentyl-1H-indazole-3-carboxamide; ---------- **

(E) 5F-AKB-48, or N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ---------- 7049**

(F) STS-135, or N-(1-adamantyl)-1-(5-fluoropentyl)indole-3-carboxamide; ---------- **

(x) Tetramethylcyclopropylcarbonylindoles or any compound structurally derived from 3-(2,2,3,3-tetramethylcyclopropylcarbonyl) indole by substitution at the nitrogen atom of the indole ring with alkyl,haloalkyl, alkenyl, cyanoalkyl, hydroxyalkyl, cycloalkylmethyl, cycloalkylethyl, (N-methylpiperidin-2-yl)methyl or 2-(4-morpholinyl)ethyl, whether or not further substituted in the indole ring to any extent, including without limitation the following: ---------- **

(A) UR-144, or (1-pentylindol-3-yl)-(2,2,3,3-tetramethylcyclopropyl)methanone; ---------- **

(B) XLR-11, or [1-(5-fluoropentyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; ---------- **

(C) A-796,260, or [1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ---------- **

(D) 5-Chloro-UR-144, or ([-(5-chloropentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; ---------- **

(E) 5-Bromo-UR-144, or [1-(5-bromopentyl)-1H-indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone; and ---------- **

(F) A-834,735, or 1-(tetrahydropyran-4-ylmethyl)-1H-indol-3-yl]-(2,2,3,3-tetramethylcyclopropyl)methanone; ---------- **

(xi) Unclassified Synthetic Cannabinoids, including without limitation the following: ---------- **

(A) CP 50556-1 hydrochloride, or [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl]oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] Acetate; ---------- **

(B) HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ---------- **

(C) HU-211, or Dexanabinol,(6aS,10aS)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol; ---------- **

(D) Dimethylheptylpyran or DMHP; ---------- **

(E) WIN55,212-2, or 2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl)pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl-1-naphthalenylmethanone; ---------- **

(F) URB597, or [3-(3-carbamoylphenyl)phenyl] N-Cyclohexylcarbamate; ---------- **

(G) URB754, or 6-methyl-2-[(4-methylphenyl)amino]-1-benzoxazin-4-one; ---------- **

(H) CB-13, or 1-naphthalenyl[4-(pentyloxy)-1 naphthalenyl]-methanone; ---------- **

a) URB602, or cyclohexyl N-(3-phenylphenyl)carbamate; ---------- **

(I) PB-22, or quinolin-8-yl 1-(5-pentyl)-1H-indole-3-carboxylate; ---------- **

(J) 5F-PB-22, or quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate; ---------- **

(K) BB-22, or quinolin-8-yl 1-(cyclohexylmethyl)-1H-indole-3-carboxylate; ---------- **

(L) NNEI (MN-24), or N-1-naphthalenyl-1-pentyl-1H-indole-3-carboxamide; ---------- **

(M) 5F-NNEI, or 1-(5-fluoropentyl)-N-(naphthalene-1-yl)-1H-indole-3-carboxamide; ---------- **

(N) 5-Fluoro-AMB, or n-[[1-(5-fluoropentyl)-1H-indazol-3-yl]carbonyl]-L-valine methyl ester ---------- 7033-(9-2018)

(O) MMB-CHMICA,or methyl-(1-cyclohexylmethyl)-1H-indole-3-carbonyl)-L-valinate ---------- 7044-(9-2018)

(P) 5-Fluoro-ADB, or methyl 2-(1-(5-fluoropentyl)-1H- indazole-3-carboxamido)-3,3-dimethylbutanoate; ---------- 7034-(11-2018)

(Q) 5-Fluoro-MDMB-PICA, or methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate ---------- 7041-(11-2018)

(R) MDMB-CHMICA, or methyl 2-(1-(cyclohexylmethyl)-1H- indole-3-carboxamido)-3,3-dimethylbutanoate; ---------- 7042-(11-2018)

(S) FUB-AMB, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate; ---------- 7021-(11-2018)

(T) MDMB-FUBINACA, or methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ---------- 7020-(11-2018)

(U) AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-caroboxamide; ---------- 7023-(7-2019)

(V) AB-CHMINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide; ---------- 7031-(7-2019)

(W) MAB-CHMINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide;- ---------- (11-2014)

(X) AB-FUBINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide;- ---------- (9-2018)

(Y) ADB-PINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide;---------- (9-2018)

(Z) 5F-CUMYL-PINACA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide ---------- 7083-(6-2020)

(AA) ADB-FUBINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide---------- 7010-(4-2021)

(BB) 4-Fluoro-MDMB-BUTINACA, or methyl(S)-2-(1-(4-fluorobutyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate; ---------- 7043-(4-2021)

(CC) 5F-AB-PINACA, or N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide ---------- 7025-(5-2022)

(DD) 4-CN-CUMYL-BUTINACA, or 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide ---------- 7089 –(5-2022)

(EE) 5F-CUMYL-P7AICA, or 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide ---------- 7085-(5-2022)

(FF) NM2201, or Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate ---------- 7221-(5-2022)

(GG) 5F-EDMB-PINACA, or Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate ---------- 7036

(HH) FUB-144, or (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl) methanone; ---------- 7014

(II) FUB-AKB48, or N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide; ---------- 7047

(JJ) MDMB-4en-PINACA, or Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate;

(KK) CH-PIATA, or N-cyclohexyl-2-(1-pentylindol-3-yl)acetamide;

(LL) ADB-BUTINACA, or N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide ---------- 7027

(6) A synthetic substance, derivative, or its isomers with:

(i) Similar chemical structure to any substance described in subdivisions (a)(1)-(a)(5) of this section; or ---------- **

(ii) Similar pharmacological effects to any substance described in subdivisions (a)(1)-(a)(5) of this section. ---------- **

(b) However, except as provided under subsection (c) of this section, the Secretary shall not delete a controlled substance listed in this section from Schedule VI.

(c) A prescription drug approved by the United States Food and Drug Administration under 21 U.S.C. § 355 is excluded from Schedule VI unless the secretary objects under § 5-64-201.

*-Scheduled before April, 1979.

**-Schedule VI is revised to conform to Act 329 of 2013.

*** - Schedule VI is revised further to conform to Act 629 of 2023. Each substance added to the Controlled Substances List pursuant to Act 629 of 2023 shall have the following effective dates:

(a) For persons who are under twenty-one (21) years of age, the effective date shall be the effective date of Act 629 of 2023; and,

(b) For persons who are twenty-one (21) years of age or older, the effective date shall be August 1, 2023.

**** Pursuant to ongoing litigation, and a preliminary injunction against enforcing Act 629 of 2023, the changes made to the List of Controlled Substances pursuant to Act 629 of 2023 are not enforceable until a final order issued in the matter, Bio Gen, LLC, et al. v. Sarah Huckabee Sanders, et al., Case No. 4:23-CV-00718-BRW, Central Division, Eastern District of Arkansas, United States District Court.